Alkermes
NASDAQ: ALKSFounded 1987 · 2,446 employees on LinkedIn · 4 known investors
Find your way into Alkermes
Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders. The company leverages neuroscience expertise to create treatments for patients with complex conditions that are traditionally underserved.
Founders & leadership
RF
Richard F. PopsChief Executive Officer and Chairman of the Board
JR
Joshua ReedinChief Financial Officer
BC
Blair C. JacksoninChief Executive OfficerBlair C. Jackson is President and CEO of Alkermes, a pharmaceutical company developing medicines for psychiatric and neurological disorders. Jackson has led cross-functional initiatives and strategic transitions throughout a career focused on operational rigor, organizational effectiveness, and integrating science with business strategy.
DJ
David J. GaffininSenior Vice President, Chief Legal Officer and Chief Compliance Officer, Alkermes, Inc.
CC
Craig C. HopkinsonExecutive Vice President, Research and Development and Chief Medical Officer
CT
C. Todd NicholsinChief Commercial OfficerTodd Nichols is Senior Vice President and Chief Commercial Officer at Alkermes, where he oversees commercial strategy for psychiatric and neurological treatments. He has held leadership roles spanning marketing, sales, and general management across multiple therapeutic areas including psychiatry, neurology, rare disease, and specialty care.
Investors · 4
Competitors · 1
by search overlap
Companies competing with Alkermes for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Alkermes to Report Second Quarter Financial Results on July 28, 2026 - BioSpacebiospace.com · Jul 2026
Is Alkermes (ALKS) Fully Priced As Russell 2000 Index Inclusion Draws Fresh Attention? - Simply Wall St Newssimplywall.st · Jul 2026Frequently asked questions
- What does Alkermes do?
- Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders. The company leverages neuroscience expertise to create treatments for patients with complex conditions that are traditionally underserved.
- Who are Alkermes's investors?
- Alkermes's investors include Bain Capital Life Sciences, Cardinal Partners, Vedanta Capital, Hatteras Venture Partners.